Yesterday at EASL 2026

New 48-week MASH data just dropped for the GLP-1 the biohacking world loves for a different reason

Yesterday, May 28, 2026, Altimmune presented 48-week data from its IMPACT Phase 2b trial at the European Association for the Study of the Liver annual congress in Milan. The numbers that arrived are about liver disease — specifically metabolic dysfunction-associated steatohepatitis, the progressive liver condition formerly known as NASH that affects an estimated one in seventeen U.S. adults and causes cirrhosis if untreated. In the IMPACT trial, 32.4% of pemvidutide-treated patients achieved the composite liver improvement endpoint — a reduction in ELF score plus a drop in liver stiffness measurement — compared to 3.2% of placebo patients. Triglycerides fell 23.7%. Total cholesterol dropped 15.4%. Waist circumference shrank 5.3 cm. Weight came down 7.5% at 48 weeks. The [GlobeNewsWire press release](https://www.globenewswire.com/news-release/2026/05/28/3303064/0/en/Pemvidutide-Demonstrates-Significant-Metabolic-Improvements-in-Patients-with-MASH-in-New-48-Week-IMPACT-Phase-2b-Data-Presented-at-EASL-2026.html) carries the full data set. What was absent from the EASL slides: lean mass. The number the wellness internet has been citing for the past two years — only 21.9% of weight lost was lean tissue, compared to roughly 39% with semaglutide — lives in a separate trial, measuring a separate endpoint, in a different patient population. MASH trials measure livers.

The actual biology

The 1:1 GLP-1 and glucagon ratio — and why the glucagon half connects fat cells and liver cells

Pemvidutide is engineered as a balanced 1:1 dual agonist at GLP-1 and glucagon receptors, and the ratio is a deliberate design choice. GLP-1 receptor agonism is the mechanism behind the current obesity drug class: suppressed appetite, slowed gastric emptying, glucose-dependent insulin secretion. Glucagon receptor activation works differently. It drives hepatic fat oxidation — the liver mobilizing stored triglycerides as fuel rather than accumulating them — and increases thermogenesis, shifting the body toward preferential fat burning during caloric deficit. The hypothesis is that the glucagon component directs which tissue energy comes from: adipose rather than lean. That is the mechanistic story behind the lean mass preservation claim. It is also the reason pemvidutide ended up in a liver disease program. Glucagon receptor activation in the liver directly opposes the steatotic process that characterizes MASH: fat accumulation in hepatocytes, inflammation, and progressive fibrosis. The [PubMed literature on pemvidutide](https://pubmed.ncbi.nlm.nih.gov/?term=pemvidutide) documents the mechanistic work that preceded both clinical programs and traces how the same dual receptor pharmacology generates hypotheses in obesity, liver disease, and body composition contexts simultaneously. The biology connects all three. The clinical trials are sorting out which of those hypotheses holds under controlled conditions.

What the internet says

The wellness community claimed the lean mass story from MOMENTUM and has been running with it since

The biohacking internet's framing of pemvidutide is built on one data point from the MOMENTUM Phase 2 obesity trial: only 21.9% of weight lost was lean mass, compared to approximately 39% with semaglutide in comparable arms. That comparison traveled fast. Once those numbers circulated through wellness podcasts, longevity forums, and coach-adjacent channels in 2024 and 2025, pemvidutide became the GLP-1 that won't steal your muscle — the alternative framing for people concerned about the body composition tradeoffs of semaglutide and tirzepatide. The mechanism behind that claim is real. Glucagon receptor activation does produce preferential fat oxidation in the relevant models, and the MOMENTUM Phase 2 data supported the hypothesis in a controlled human trial. What gets compressed in that storytelling is everything else about the drug's actual development path. Pemvidutide received FDA Breakthrough Therapy designation not for obesity or body composition but for MASH. The Phase 3 trial infrastructure being built for the second half of 2026 — the PERFORMA trial — is a liver disease program. The obesity program that produced the lean mass story remains at an earlier clinical stage. The wellness internet adopted the body composition narrative from a 24-week Phase 2 trial as the defining story of this drug, two years before either a MASH approval or an obesity Phase 3 readout exists.

What the data actually shows

MOMENTUM and IMPACT are both real trials — they just asked entirely different questions

The MOMENTUM Phase 2 trial enrolled adults with overweight or obesity and tested pemvidutide over 24 to 36 weeks with weight loss and body composition endpoints. The lean mass finding — documented in [2 Minute Medicine's summary](https://www.2minutemedicine.com/altimmune-glp-1-glucagon-receptor-agonist-pemvidutide-preserves-lean-mass-during-weight-loss/) of data first presented at the American Diabetes Association's 84th Scientific Sessions — is real Phase 2 data from a controlled trial. An extended MOMENTUM analysis from 2025 reported 22.1% weight loss with 92% fat mass composition at higher doses, representing the strongest body composition outcome published in the Phase 2 GLP-1 literature. The IMPACT Phase 2b trial is a separate program: separate enrollment, separate endpoints. It enrolled confirmed MASH patients and evaluated liver-specific composite measures over 48 weeks — fibrosis markers, liver stiffness, metabolic panel outcomes. The data presented at EASL 2026 yesterday met those endpoints. Neither trial is the other trial. [ClinicalTrials.gov for pemvidutide](https://clinicaltrials.gov/search?term=pemvidutide) shows MOMENTUM and IMPACT registered separately with distinct protocols, distinct primary endpoints, and distinct patient populations, alongside the forthcoming PERFORMA Phase 3 MASH program. The compound has Phase 2 human evidence in two disease contexts. The lean mass finding does not apply to the MASH program because the MASH program was not designed to measure it.

Early human — PeptideFactCheck stance

Real Phase 2 data in two programs — and a Phase 3 calendar that has not started on the question wellness is asking

Pemvidutide carries the Early human evidence tier on PeptideFactCheck because it has real, peer-reviewed human clinical data — Phase 2 trials with meaningful endpoints met, a Breakthrough Therapy designation from FDA, and a Phase 3 MASH program launching later this year. It remains investigational rather than approved for any indication. The MASH Phase 3 trial expected to begin in H2 2026 will generate the pivotal controlled data for that indication. The obesity Phase 3 program, which would be the regulatory home for any broad weight-management approval and the path toward validating the lean mass story at scale, remains at a planning stage. The MOMENTUM lean mass finding is real Phase 2 data with a real mechanism behind it. It is not a Phase 3 result. It is not an approved label. It is not evidence that any specific outcome will be reproduced in the larger controlled trial that would establish it. Early human describes exactly where this evidence sits: interesting enough to watch, too early for broad certainty. The EASL 2026 data from yesterday is a real milestone for the MASH program. The FDA Breakthrough Therapy designation is a real signal that the agency found sufficient evidence to expedite development review. Neither of those facts moves the lean mass story closer to a Phase 3 confirmation. Those are different programs, different calendars, and different standards of certainty — and the evidence tier is designed to preserve that distinction rather than flatten it.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.